VIOLET Pharmaceuticals

VIOLET Pharmaceuticals is a preclinical stage biopharma company developing a First-in-Class mRNA therapy against metastatic cancers. The company develops nanotherapies improving immunotherapies’ efficiency and approved indications (e.g. Immune Checkpoints Inhibitors (ICI)) by increasing the whole Antigen Presentation Machinery (APM) in tumor cells. Our assets are the LCOR mRNA NanoTherapies, used in combination with immunotherapies. Our technology is backed by Top-Notch science (published in 2 “Nature”) and has a strong IP position (3 patents). We achieved radical complete responses of our LCOR mRNA NanoTherapy in combination with ICI in several preclinical breast cancer tumors and metastasis models. LCOR specifically modulates the whole APM which determines immune detection (tumor visibility) and immunotherapy response. There are currently no specific APM-modulating therapies on the market, only competitors with indirect APM modulation. Therefore, our gene therapy represents an unprecedented opportunity to reconfigure tumor immunity and enhance immunotherapies efficiency. VIOLET Pharmaceuticals : Visibility to Immuno-Oncology & Lymphocyte Enhancing Therapies